CompletedNCT02694328

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Researchers compared ALKS 3831 and Olanzapine to find out how the approaches affected body weight in adults with schizophrenia.

Medication studyAges 18–55United States

The study in practice

Understand this study

Researchers compared ALKS 3831 and Olanzapine to find out how the approaches affected body weight in adults with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Little Rock and 53 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateStarted: March 2, 2016

Recruitment status: Completed
Enrollment listed in the registry: 561
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT02694328
Official title: Show the full official title
A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia

Completed

Little Rock, United States · Springdale, United States · Anaheim, United States

47 more locations

FAQ

What did researchers investigate?

Researchers compared ALKS 3831 and Olanzapine to find out how the approaches affected body weight in adults with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including ALKS 3831 and Olanzapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.